# Usage of Dapagliflozin in the Management of Type-2 Diabetes Mellitus: A Real World Evidence Study in Indian Patients

> **NCT03071016** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 2000 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03071016
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-04
- **Primary completion:** 2018-03-03
- **Final completion:** 2018-03-03
- **Target enrollment:** 2000 (ACTUAL)
- **Last updated:** 2019-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03071016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03071016, "Usage of Dapagliflozin in the Management of Type-2 Diabetes Mellitus: A Real World Evidence Study in Indian Patients". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03071016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*